RecruitingNCT07557498
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community
Sponsor
Bristol-Myers Squibb
Enrollment
362 participants
Start Date
Jan 15, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Phase I: retrospective chart review
- For inclusion in the study, participants must meet ALL of the following criteria:
- Are an adult aged 18 or over at baseline
- Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
- Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024
- Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)
- Are not enrolled in any interventional clinical trial at study baseline
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMavacamten
According to the product label
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07557498